XORTX Therapeutics Inc. (XRTX) announced submission of a new patent for the treatment of chronic kidney disease. The patent entitled "Oral and Sublingual Formulations of Xanthine Oxidase Inhibitors and Methods of Treating Disease" outlines new formulations and methods for safer and more effective the use of xanthine oxidase inhibitors in the setting of chronic kidney disease in particular autosomal dominant polycystic kidney disease, diabetic nephropathy, IgA nephropathy, lupus nephritis and focal segmental glomerulosclerosis.